▼Tecentriq is subject to additional monitoring in Great Britain. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. In Northern Ireland, a black triangle is not required for Tecentriq and it is not subject to additional monitoring.

Adverse events should be reported. Reporting forms and information can be found at  www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44(0)1707 367554.

As Tecentriq is a biological medicine, healthcare professionals should report adverse reactions by brand name and batch number.

Learn more about TECENTRIQ®▼ (atezolizumab), a cancer immunotherapy treatment, by clicking on the respective indication of interest:

 

Lung

HCC

Non-small cell lung cancer (NSCLC):1-2

Tecentriq® is indicated as 1L monotherapy for adult patients with metastatic non-small cell lung cancer (NSCLC ) whose tumours have a PD- L1 expression ≥ 50 % tumour cells (TC ) or ≥10% tumour-infiltrating immune cells (IC ) and who do not have EGFR mutant or ALK- positive NSCLC. Please click here for more information

Tecentriq® as monotherapy is indicated as adjuvant treatment following complete resection for adult patients with Stage II to IIIA (7th edition of the UICC/AJCC-staging system) non-small cell lung cancer (NSCLC) whose tumours have PD-L1 expression on ≥ 50% of tumour cells (TC) and whose disease has not progressed following platinum-based adjuvant chemotherapy. Please click here for more information

Tecentriq®, in combination with Avastin® (bevacizumab), paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq®, in combination with Avastin® (bevacizumab), paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies. 

Tecentriq® as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK-positive NSCLC should also have received targeted therapies before receiving Tecentriq®.

Tecentriq®, in combination with nab-paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK-positive NSCLC. 

Small cell lung cancer (SCLC):1,2

Tecentriq®, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).

Hepatocellular carcinoma1,2

Tecentriq®, in combination with Avastin® (bevacizumab), is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. Please click here for more information

Triple-negative breast cancer (TNBC):1,2

Tecentriq® in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease. 

 

Urothelial carcinoma (UC): 1,2

Tecentriq® as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma:

  • after prior platinum-containing chemotherapy, or
  • who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5%

 

References:

  1. Tecentriq Summary of Product Characteristics – Great Britain
  2. Tecentriq Summary of Product Characteristics – Northern Ireland






M-GB-00006950
Date of preparation: May 2022